Table 4. Polymorphisms’ effect on anti−/pro-inflammatory signal and chance of good anti-TNF response (EULAR good/moderate or ACR50).
| GENE/PROTEIN (SNP) | ProteinInflammatoryeffect | Variant allele Expectedeffect on geneexpression | Variant alleleAssociation withAnti-TNF response | Subgroup |
| NLRP3/NLRP3 | Pro- | ↓[25] | ↓* | All |
| rs4612666 C>T | Smokers | |||
| Seropositive | ||||
| Infliximab | ||||
| TNFRS1A/TNFR1 | Pro- | ↑[32] | ↓* | Seropositive |
| rs4149570 G>T | Etanercept | |||
| IL17A/IL-17 | Pro- | ↑[33] | ↑# | Seropositive |
| rs2275913 G>A | ||||
| TLR4/TLR4 | Pro- | Unknown | ↑# | All |
| rs5030728 G>A | ||||
| IL1B/IL-1β | Pro- | ↑[34] | ↑# | All |
| rs1143623 G>C | Seropositive | |||
| IL1B/IL-1β | Pro- | ↓[34] | ↑* | Infliximab |
| rs4848306 | ||||
| LY96/MD-2 | Pro- | ↑[35] | ↑* | Infliximab |
| rs11465996 C>G | ||||
| INFG/Interferon-γ | Pro−/Anti- | ↓[36] | ↓* | All |
| rs2430561 T>A | Seropositive |
EULAR (*): European League Against Rheumatism ACR50 (#): American College of Rheumatology response criterion (50% improvement).